Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | UBE2N | P61088 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116289 | 0.82 | POLB (0.86) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL11014928 | 0.81 | POLB (0.83) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL7558655 | 0.81 | POLB (0.72) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL2793931 | 0.80 | POLB (0.75) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL7558870 | 0.80 | LMNA (0.71) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL11174923 | 0.79 | AKR1B1 (0.63) | SMN1; SMN2RXFP1ADORA2BGLATSHR | |
| SCHEMBL7608305 | 0.78 | POLB (0.75) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL7562065 | 0.78 | POLB (0.71) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL7564474 | 0.77 | POLB (0.73) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL6346960 | 0.77 | POLB (0.69) | POLBHIF1ASMN1; SMN2RXFP1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT | 2002-01-24 | — | — | US | disclosed |
| EP-0758239-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995026727-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | EPX, XDH, MPO | POLB 2681/4885HIF1A 2305/4885SMN1; SMN2 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.